Profile data is unavailable for this security.

About the company

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

  • Revenue in USD (TTM)30.40bn
  • Net income in USD2.33bn
  • Incorporated1900
  • Employees99.00k
  • Location
    Abbott Laboratories100 Abbott Park RdABBOTT PARK 60064-3500United StatesUSA
  • Phone+1 (224) 667-6100
  • Websitehttp://www.abbott.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Edwards Lifesciences Corp3.63bn976.30m34.10bn12.20k35.5910.1532.339.394.583.3317.0416.080.63491.688.09297,836.1017.0616.7720.6619.5474.1374.1226.8723.701.85--0.2620.0015.9112.5854.1224.668.63--
Baxter International Inc11.06bn1.80bn35.65bn47.00k20.343.9113.753.223.292.2020.2317.120.64333.846.19235,319.2010.476.9812.398.9743.2242.1416.2714.641.96203.000.276846.633.92-5.40-73.64-10.53-11.40-17.23
Boston Scientific Corporation9.67bn1.52bn51.34bn29.00k34.026.1921.455.311.090.46996.945.990.49572.526.34333,448.307.810.948610.471.1371.2169.8015.752.110.558212.350.44430.007.894.53178.10--12.66--
Intuitive Surgical, Inc.3.57bn1.14bn58.89bn4.44k52.749.3846.6316.499.786.7030.5355.000.55083.596.81803,352.8017.6014.0119.6115.6270.0768.7331.9526.895.52--0.000.0015.707.5132.878.296.10--
Becton Dickinson and Co15.98bn800.00m63.19bn76.03k78.583.0122.753.953.000.442361.4778.270.34884.097.87210,
Stryker Corporation13.28bn2.07bn64.59bn33.00k31.596.5523.194.875.463.2435.0426.360.60941.686.57402,303.009.507.3911.449.1166.2566.3515.5812.331.21--0.422141.249.887.5312.517.3823.2814.87
Thermo Fisher Scientific Inc.23.90bn2.77bn97.13bn70.00k35.293.6119.214.066.846.3358.8966.790.43044.356.37341,397.205.004.725.615.3044.3644.8011.6111.
Abbott Laboratories30.40bn2.33bn127.39bn99.00k54.944.1522.404.191.320.495317.2417.480.42263.516.04307,090.903.243.683.794.5458.0255.357.668.471.134.200.432679.6831.357.5370.5650.22-8.76-12.01
Medtronic PLC30.38bn4.70bn128.54bn86.00k27.722.6017.474.233.451.6522.3136.850.33272.425.29353,232.605.164.635.775.1870.5269.6815.5114.992.117.580.334850.150.817912.5438.039.9118.5012.09
Data as of Dec 13 2018. Currency figures normalised to Abbott Laboratories's reporting currency: US Dollar USD

Institutional shareholders

32.68%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 2018136.45m7.77%
Capital Research & Management Co. (Global Investors)as of 30 Sep 2018125.17m7.13%
BlackRock Fund Advisorsas of 30 Sep 201878.53m4.47%
SSgA Funds Management, Inc.as of 30 Sep 201870.13m3.99%
Wellington Management Co. LLPas of 30 Sep 201841.38m2.36%
Massachusetts Financial Services Co.as of 30 Sep 201838.60m2.20%
Northern Trust Investments, Inc.as of 30 Sep 201825.90m1.47%
Geode Capital Management LLCas of 30 Sep 201820.36m1.16%
Capital Research & Management Co. (International Investors)as of 30 Sep 201819.87m1.13%
Norges Bank Investment Managementas of 31 Dec 201717.59m1.00%
More ▼
Data from 31 Dec 2017 - 30 Sep 2018Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.